Gene therapy for dopamine replacement in Parkinson's disease
Anders Björklund1, Tomas Björklund, Deniz Kirik
1Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden. anders.bjorklund@med.lu.se
Science Translational Medicine
|April 7, 2010
Summary
Gene therapy offers a potential solution for Parkinson's disease (PD) by restoring dopamine synthesis. Promising results in primate models suggest this enzyme-replacement approach could advance to human clinical trials, overcoming L-dopa side effects.
Area of Science:
- Neuroscience
- Gene Therapy
- Parkinson's Disease Research
Background:
- Levodopa (L-dopa) therapy revolutionized Parkinson's disease (PD) treatment but causes long-term side effects like dyskinesias.
- Current treatments struggle to provide consistent dopamine levels and manage motor fluctuations.
Purpose of the Study:
- To evaluate a gene therapy approach for restoring dopamine synthesis in a nonhuman primate model of PD.
- To assess the potential of enzyme-replacement therapy via viral vectors as an alternative to oral L-dopa.
Main Methods:
- Utilized viral vectors to deliver genes encoding dopamine-synthesizing enzymes into the affected brain regions.
- Tested the efficacy and safety of this gene therapy in a nonhuman primate model exhibiting PD symptoms.
Main Results:
- Demonstrated promising results in restoring dopamine synthesis in the primate model.
- Indicated a potential to mitigate the side effects associated with chronic L-dopa treatment.
Conclusions:
- Gene therapy represents a viable strategy for treating Parkinson's disease.
- The enzyme-replacement approach shows potential for future clinical trials in PD patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.